{"id": "article-23408_0", "title": "Immunotherapy -- Continuing Education Activity", "content": "Immunotherapy is a pivotal intervention in managing a spectrum of immunological disorders, from immunodeficiencies to malignancies. This\u00a0activity\u00a0discusses\u00a0the diverse modalities of immunotherapy, their mechanisms of action, potential adverse events, and crucial considerations such as dosing and monitoring. Participants will explore the conditions amenable to immunotherapeutic interventions\u00a0to better comprehend immunotherapy's role in enhancing the quality of life and longevity of afflicted individuals.\u00a0Attendees will gain additional insights into immunotherapeutic agents by discussing their pharmacodynamics, pharmacokinetics, and pertinent interactions. By fostering a comprehensive understanding of immunotherapeutic principles, this program empowers healthcare teams to deliver personalized, efficacious care to patients navigating immunological challenges, thereby advancing the frontier of modern medicine.", "contents": "Immunotherapy -- Continuing Education Activity. Immunotherapy is a pivotal intervention in managing a spectrum of immunological disorders, from immunodeficiencies to malignancies. This\u00a0activity\u00a0discusses\u00a0the diverse modalities of immunotherapy, their mechanisms of action, potential adverse events, and crucial considerations such as dosing and monitoring. Participants will explore the conditions amenable to immunotherapeutic interventions\u00a0to better comprehend immunotherapy's role in enhancing the quality of life and longevity of afflicted individuals.\u00a0Attendees will gain additional insights into immunotherapeutic agents by discussing their pharmacodynamics, pharmacokinetics, and pertinent interactions. By fostering a comprehensive understanding of immunotherapeutic principles, this program empowers healthcare teams to deliver personalized, efficacious care to patients navigating immunological challenges, thereby advancing the frontier of modern medicine."}
{"id": "article-23408_1", "title": "Immunotherapy -- Continuing Education Activity", "content": "Objectives: Identify different categories of immunotherapy. Determine\u00a0indicated conditions for each type of immunotherapy. Identify\u00a0some of the contraindications of various forms of immunotherapy. Select\u00a0interprofessional team strategies for improving care coordination and communication to advance immunotherapy, improve outcomes, and minimize adverse events. Access free multiple choice questions on this topic.", "contents": "Immunotherapy -- Continuing Education Activity. Objectives: Identify different categories of immunotherapy. Determine\u00a0indicated conditions for each type of immunotherapy. Identify\u00a0some of the contraindications of various forms of immunotherapy. Select\u00a0interprofessional team strategies for improving care coordination and communication to advance immunotherapy, improve outcomes, and minimize adverse events. Access free multiple choice questions on this topic."}
{"id": "article-23408_2", "title": "Immunotherapy -- Indications", "content": "Immunotherapy is the use of drugs (eg, immunosuppressors), biologicals (eg, cytokines, monoclonal antibodies, and antisera), vitamins and minerals (eg, zinc, vitamin C, and vitamin B6), transplantation (eg, bone marrow), and immunizations (eg, prophylactic and therapeutic vaccines) to control immune responses. For example, immunotherapy works to upregulate or downregulate the immune system to achieve a therapeutic effect in immunologically mediated disorders, including immunodeficiencies, hypersensitivity reactions, autoimmune diseases, tissue and organ transplantations, malignancies, inflammatory disorders, infectious diseases, and any other disease, where immunotherapy can improve the quality and life expectancy. [1] [2] [3] [4] [5] [6]", "contents": "Immunotherapy -- Indications. Immunotherapy is the use of drugs (eg, immunosuppressors), biologicals (eg, cytokines, monoclonal antibodies, and antisera), vitamins and minerals (eg, zinc, vitamin C, and vitamin B6), transplantation (eg, bone marrow), and immunizations (eg, prophylactic and therapeutic vaccines) to control immune responses. For example, immunotherapy works to upregulate or downregulate the immune system to achieve a therapeutic effect in immunologically mediated disorders, including immunodeficiencies, hypersensitivity reactions, autoimmune diseases, tissue and organ transplantations, malignancies, inflammatory disorders, infectious diseases, and any other disease, where immunotherapy can improve the quality and life expectancy. [1] [2] [3] [4] [5] [6]"}
{"id": "article-23408_3", "title": "Immunotherapy -- Indications", "content": "Clinicians describe the use of immunotherapy in some essential disorders of the immune system. The use of immunoglobulins, transfer factor, immunosuppressors, monoclonal antibodies, cytokines, nutritional supplements, and transplantation is listed below.", "contents": "Immunotherapy -- Indications. Clinicians describe the use of immunotherapy in some essential disorders of the immune system. The use of immunoglobulins, transfer factor, immunosuppressors, monoclonal antibodies, cytokines, nutritional supplements, and transplantation is listed below."}
{"id": "article-23408_4", "title": "Immunotherapy -- Indications -- Immunoglobulin Therapy", "content": "X-linked agammaglobulinemia Transient hypogammaglobulinemia of infancy Variable common immunodeficiency Selective immunoglobulin deficiencies (except for IgA) Hyper-IgM syndrome Lupus-like syndromes", "contents": "Immunotherapy -- Indications -- Immunoglobulin Therapy. X-linked agammaglobulinemia Transient hypogammaglobulinemia of infancy Variable common immunodeficiency Selective immunoglobulin deficiencies (except for IgA) Hyper-IgM syndrome Lupus-like syndromes"}
{"id": "article-23408_5", "title": "Immunotherapy -- Indications -- Use of Transfer Factor (Dialysable Leukocyte Extract)", "content": "Interstitial pneumonia in acquired immunodeficient states Recurrent viral infections in\u00a0immunodeficiency syndromes Chronic mucocutaneous candidiasis Primary tuberculosis with immunodeficiency Wiskott-Aldrich syndrome Severe combined immunodeficiency disease (SCID) Chronic active hepatitis Coccidioidomycosis Beh\u00e7et disease Aphthous stomatitis Familial keratoacanthoma Malignancy", "contents": "Immunotherapy -- Indications -- Use of Transfer Factor (Dialysable Leukocyte Extract). Interstitial pneumonia in acquired immunodeficient states Recurrent viral infections in\u00a0immunodeficiency syndromes Chronic mucocutaneous candidiasis Primary tuberculosis with immunodeficiency Wiskott-Aldrich syndrome Severe combined immunodeficiency disease (SCID) Chronic active hepatitis Coccidioidomycosis Beh\u00e7et disease Aphthous stomatitis Familial keratoacanthoma Malignancy"}
{"id": "article-23408_6", "title": "Immunotherapy -- Indications -- Use of Immunosuppressors", "content": "Systemic lupus erythematosus (SLE) Wiskott-Aldrich syndrome Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy Autoimmune lymphoproliferative syndrome Idiopathic CD4+ lymphocytopenia Complement system deficiencies Various malignancies", "contents": "Immunotherapy -- Indications -- Use of Immunosuppressors. Systemic lupus erythematosus (SLE) Wiskott-Aldrich syndrome Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy Autoimmune lymphoproliferative syndrome Idiopathic CD4+ lymphocytopenia Complement system deficiencies Various malignancies"}
{"id": "article-23408_7", "title": "Immunotherapy -- Indications -- Transplantation", "content": "Bone marrow transplant RAG-1/RAG-2 SCID ADA-SCID Artemis SCID Wiskott-Aldrich syndrome X-linked agammaglobulinemia Acute leukemia Thymus transplant DiGeorge syndrome", "contents": "Immunotherapy -- Indications -- Transplantation. Bone marrow transplant RAG-1/RAG-2 SCID ADA-SCID Artemis SCID Wiskott-Aldrich syndrome X-linked agammaglobulinemia Acute leukemia Thymus transplant DiGeorge syndrome"}
{"id": "article-23408_8", "title": "Immunotherapy -- Indications -- Immunizations", "content": "Diphtheria, tetanus, and pertussis (DTP) Inactivated Polio vaccine Measles, Mumps, and Rubella Pneumococcal conjugate Hemophilus B conjugate Hepatitis B Varicella Bacille Calmette-Gu\u00e9rin (BCG) Human Papillomavirus (HPV) Meningococcal vaccine Cholera vaccine Rotavirus vaccine Yellow fever vaccine Dengue vaccine", "contents": "Immunotherapy -- Indications -- Immunizations. Diphtheria, tetanus, and pertussis (DTP) Inactivated Polio vaccine Measles, Mumps, and Rubella Pneumococcal conjugate Hemophilus B conjugate Hepatitis B Varicella Bacille Calmette-Gu\u00e9rin (BCG) Human Papillomavirus (HPV) Meningococcal vaccine Cholera vaccine Rotavirus vaccine Yellow fever vaccine Dengue vaccine"}
{"id": "article-23408_9", "title": "Immunotherapy -- Indications -- Use of Cytokines in the Immunotherapy of Advanced Malignancies", "content": "Interleukin-2 Interleukin-7 Interleukin-12 Interleukin-18 Interleukin-21", "contents": "Immunotherapy -- Indications -- Use of Cytokines in the Immunotherapy of Advanced Malignancies. Interleukin-2 Interleukin-7 Interleukin-12 Interleukin-18 Interleukin-21"}
{"id": "article-23408_10", "title": "Immunotherapy -- Indications -- Use of Nutritional Supplements (Vitamins A, C, E, and B6, Iron, Zinc, Selenium, and Copper)", "content": "Primary immunodeficiency with malnutrition Lymphoma Malignancies in general Graft-versus-host reaction Diseases with impaired cell-mediated immunity Recurrent and chronic bacterial infections SCID HIV/AIDS Burns", "contents": "Immunotherapy -- Indications -- Use of Nutritional Supplements (Vitamins A, C, E, and B6, Iron, Zinc, Selenium, and Copper). Primary immunodeficiency with malnutrition Lymphoma Malignancies in general Graft-versus-host reaction Diseases with impaired cell-mediated immunity Recurrent and chronic bacterial infections SCID HIV/AIDS Burns"}
{"id": "article-23408_11", "title": "Immunotherapy -- Indications -- Phase III Clinical Trials of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib", "content": "Relapsed or refractory chronic lymphocytic leukemia Small lymphocytic lymphoma Relapsed or refractory Mantle cell lymphoma Newly diagnosed non-germinal center B-cell subtype of diffuse large B-cell lymphoma", "contents": "Immunotherapy -- Indications -- Phase III Clinical Trials of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib. Relapsed or refractory chronic lymphocytic leukemia Small lymphocytic lymphoma Relapsed or refractory Mantle cell lymphoma Newly diagnosed non-germinal center B-cell subtype of diffuse large B-cell lymphoma"}
{"id": "article-23408_12", "title": "Immunotherapy -- Indications -- Use of Interferon Gamma", "content": "Chronic granulomatous disease Bladder carcinoma Melanoma Chagas disease Lepromatous leprosy HIV/AIDS Cryptococcal meningitis", "contents": "Immunotherapy -- Indications -- Use of Interferon Gamma. Chronic granulomatous disease Bladder carcinoma Melanoma Chagas disease Lepromatous leprosy HIV/AIDS Cryptococcal meningitis"}
{"id": "article-23408_13", "title": "Immunotherapy -- Indications -- Immune Checkpoint Inhibitors", "content": "Ipilimumab Nivolumab Pembrolizumab Atezolizumab Avelumab Durvalumab", "contents": "Immunotherapy -- Indications -- Immune Checkpoint Inhibitors. Ipilimumab Nivolumab Pembrolizumab Atezolizumab Avelumab Durvalumab"}
{"id": "article-23408_14", "title": "Immunotherapy -- Indications -- Cytokine Antagonists (IL-1RA)", "content": "Septic shock Inflammatory bowel disease Ischemia-reperfusion injury Adult respiratory distress syndrome Osteoporosis Polyarteritis nodosa Glomerulonephritis", "contents": "Immunotherapy -- Indications -- Cytokine Antagonists (IL-1RA). Septic shock Inflammatory bowel disease Ischemia-reperfusion injury Adult respiratory distress syndrome Osteoporosis Polyarteritis nodosa Glomerulonephritis"}
{"id": "article-23408_15", "title": "Immunotherapy -- Indications -- Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)", "content": "Accelerate marrow recovery after autologous bone marrow transplantation Primary neutropenia Myelodysplasia Myeloproliferative disorders AIDS Aplastic anemia Neutropenia associated with Felty syndrome", "contents": "Immunotherapy -- Indications -- Granulocyte-macrophage Colony-stimulating Factor (GM-CSF). Accelerate marrow recovery after autologous bone marrow transplantation Primary neutropenia Myelodysplasia Myeloproliferative disorders AIDS Aplastic anemia Neutropenia associated with Felty syndrome"}
{"id": "article-23408_16", "title": "Immunotherapy -- Indications -- CAR T-cell therapy", "content": "CAR T-cell therapy has primarily been investigated and approved for certain hematological malignancies, particularly B-cell malignancies. These include:", "contents": "Immunotherapy -- Indications -- CAR T-cell therapy. CAR T-cell therapy has primarily been investigated and approved for certain hematological malignancies, particularly B-cell malignancies. These include:"}
{"id": "article-23408_17", "title": "Immunotherapy -- Indications -- CAR T-cell therapy", "content": "B-cell Acute Lymphoblastic Leukemia (B-ALL): CAR T-cell therapy has\u00a0demonstrated remarkable efficacy in treating relapsed or refractory B-ALL, particularly in pediatric and young adult patients. Diffuse Large B-cell Lymphoma (DLBCL): CAR T-cell therapy has been approved for certain subtypes of DLBCL, including relapsed or refractory DLBCL after\u00a02 or more lines of systemic therapy. Follicular Lymphoma (FL): CAR T-cell therapy has demonstrated promising results in treating relapsed or refractory FL, especially in patients who have failed multiple lines of therapy. Mantle Cell Lymphoma (MCL): CAR T-cell therapy has shown efficacy in treating relapsed or refractory MCL, particularly in patients who have failed prior therapies. Chronic Lymphocytic Leukemia (CLL): While still investigational, CAR T-cell therapy is being studied in CLL, particularly in patients with high-risk disease or those who have relapsed after multiple lines of therapy.", "contents": "Immunotherapy -- Indications -- CAR T-cell therapy. B-cell Acute Lymphoblastic Leukemia (B-ALL): CAR T-cell therapy has\u00a0demonstrated remarkable efficacy in treating relapsed or refractory B-ALL, particularly in pediatric and young adult patients. Diffuse Large B-cell Lymphoma (DLBCL): CAR T-cell therapy has been approved for certain subtypes of DLBCL, including relapsed or refractory DLBCL after\u00a02 or more lines of systemic therapy. Follicular Lymphoma (FL): CAR T-cell therapy has demonstrated promising results in treating relapsed or refractory FL, especially in patients who have failed multiple lines of therapy. Mantle Cell Lymphoma (MCL): CAR T-cell therapy has shown efficacy in treating relapsed or refractory MCL, particularly in patients who have failed prior therapies. Chronic Lymphocytic Leukemia (CLL): While still investigational, CAR T-cell therapy is being studied in CLL, particularly in patients with high-risk disease or those who have relapsed after multiple lines of therapy."}
{"id": "article-23408_18", "title": "Immunotherapy -- Indications -- CAR T-cell therapy", "content": "In addition to these hematological malignancies, CAR T-cell therapy is also being investigated for certain types of solid tumors, although progress in this area has been more limited. Solid tumors being targeted with CAR T-cell therapy include: Multiple Myeloma: CAR T-cell therapy targeting BCMA (B-cell maturation antigen) has shown promise in treating relapsed or refractory multiple myeloma. Glioblastoma: CAR T-cell therapy targeting EGFRvIII (epidermal growth factor receptor variant III) has been investigated in glioblastoma, although results have been mixed. Sarcomas: CAR T-cell therapy is being explored in certain types of sarcomas, including osteosarcoma and synovial sarcoma, although research is still in the early stages.", "contents": "Immunotherapy -- Indications -- CAR T-cell therapy. In addition to these hematological malignancies, CAR T-cell therapy is also being investigated for certain types of solid tumors, although progress in this area has been more limited. Solid tumors being targeted with CAR T-cell therapy include: Multiple Myeloma: CAR T-cell therapy targeting BCMA (B-cell maturation antigen) has shown promise in treating relapsed or refractory multiple myeloma. Glioblastoma: CAR T-cell therapy targeting EGFRvIII (epidermal growth factor receptor variant III) has been investigated in glioblastoma, although results have been mixed. Sarcomas: CAR T-cell therapy is being explored in certain types of sarcomas, including osteosarcoma and synovial sarcoma, although research is still in the early stages."}
{"id": "article-23408_19", "title": "Immunotherapy -- Indications -- CAR T-cell therapy", "content": "While CAR T-cell therapy has shown significant promise in treating certain types of cancer, particularly B-cell malignancies, ongoing research is needed to expand its applicability to other cancer types and improve its efficacy and safety profile.", "contents": "Immunotherapy -- Indications -- CAR T-cell therapy. While CAR T-cell therapy has shown significant promise in treating certain types of cancer, particularly B-cell malignancies, ongoing research is needed to expand its applicability to other cancer types and improve its efficacy and safety profile."}
{"id": "article-23408_20", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "IVIG is a product\u00a0isolated\u00a0from fractionation pools of thousands of plasma donations collected in blood transfusion services. Traces of IgM, IgA, and cytokines are present in IVIG. IVIGs\u00a0have several proposed mechanisms of action including: [7] [8] [9] Effects of IVIG on activated B-lymphocytes Infusion of IVIG results in auto-IgG suppression Interaction of Fc fragment with Fc receptors Interaction of infused IgG with complement proteins Modulation of synthesis of cytokines Modulation of cell proliferation and apoptosis Remyelination Neutralizes pathogenic autoantibodies Interferes with antigen presentation Functional blockade of Fc receptors on splenic macrophages Selection of immune repertoires Neutralization of bacterial toxins and superantigens Hindrance of natural killer cell activity Inhibition of matrix metalloproteinase-9 Suppression of NF-kB activation and IkB degradation G1 cell cycle arrest Prevention of tumor growth Enhances the expansion of Tregs", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). IVIG is a product\u00a0isolated\u00a0from fractionation pools of thousands of plasma donations collected in blood transfusion services. Traces of IgM, IgA, and cytokines are present in IVIG. IVIGs\u00a0have several proposed mechanisms of action including: [7] [8] [9] Effects of IVIG on activated B-lymphocytes Infusion of IVIG results in auto-IgG suppression Interaction of Fc fragment with Fc receptors Interaction of infused IgG with complement proteins Modulation of synthesis of cytokines Modulation of cell proliferation and apoptosis Remyelination Neutralizes pathogenic autoantibodies Interferes with antigen presentation Functional blockade of Fc receptors on splenic macrophages Selection of immune repertoires Neutralization of bacterial toxins and superantigens Hindrance of natural killer cell activity Inhibition of matrix metalloproteinase-9 Suppression of NF-kB activation and IkB degradation G1 cell cycle arrest Prevention of tumor growth Enhances the expansion of Tregs"}
{"id": "article-23408_21", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "IVIG has been used with some success to improve the symptoms and clinical signs of conditions that include:", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). IVIG has been used with some success to improve the symptoms and clinical signs of conditions that include:"}
{"id": "article-23408_22", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Immune thrombocytopenic purpura (ITP)", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Immune thrombocytopenic purpura (ITP)"}
{"id": "article-23408_23", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Guillain-Barre syndrome", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Guillain-Barre syndrome"}
{"id": "article-23408_24", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Chronic inflammatory demyelinating polyneuropathy", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Chronic inflammatory demyelinating polyneuropathy"}
{"id": "article-23408_25", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Systemic lupus erythematosus (SLE)", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Systemic lupus erythematosus (SLE)"}
{"id": "article-23408_26", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Idiopathic inflammatory myopathies", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Idiopathic inflammatory myopathies"}
{"id": "article-23408_27", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "ANCA-associated vasculitis", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). ANCA-associated vasculitis"}
{"id": "article-23408_28", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Multiple motor neuropathy", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Multiple motor neuropathy"}
{"id": "article-23408_29", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Multiple sclerosis", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Multiple sclerosis"}
{"id": "article-23408_30", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Myasthenia gravis", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Myasthenia gravis"}
{"id": "article-23408_31", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Kawasaki disease", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Kawasaki disease"}
{"id": "article-23408_32", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Autoimmune uveitis", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Autoimmune uveitis"}
{"id": "article-23408_33", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Dermatomyositis", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Dermatomyositis"}
{"id": "article-23408_34", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Systemic sclerosis", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Systemic sclerosis"}
{"id": "article-23408_35", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Sj\u00f6gren syndrome", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Sj\u00f6gren syndrome"}
{"id": "article-23408_36", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Antiphospholipid antibody syndrome", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Antiphospholipid antibody syndrome"}
{"id": "article-23408_37", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Still disease", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Still disease"}
{"id": "article-23408_38", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Acute disseminated encephalomyelitis", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Acute disseminated encephalomyelitis"}
{"id": "article-23408_39", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Diabetic neuropathy", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Diabetic neuropathy"}
{"id": "article-23408_40", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Lambert-Eaton myasthenic syndrome", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Lambert-Eaton myasthenic syndrome"}
{"id": "article-23408_41", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Opsoclonus-myoclonus", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Opsoclonus-myoclonus"}
{"id": "article-23408_42", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections"}
{"id": "article-23408_43", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Polymyositis", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Polymyositis"}
{"id": "article-23408_44", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Rasmussen encephalitis", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Rasmussen encephalitis"}
{"id": "article-23408_45", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Stiff person syndrome", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Stiff person syndrome"}
{"id": "article-23408_46", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Primary immunodeficiency disorders", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Primary immunodeficiency disorders"}
{"id": "article-23408_47", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Secondary immunodeficiency disorder", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Secondary immunodeficiency disorder"}
{"id": "article-23408_48", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Chronic lymphocytic leukemia", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Chronic lymphocytic leukemia"}
{"id": "article-23408_49", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Bone marrow transplantation", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Bone marrow transplantation"}
{"id": "article-23408_50", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Treatment-induced neutropenia and thrombocytopenia", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Treatment-induced neutropenia and thrombocytopenia"}
{"id": "article-23408_51", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "AIDS", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). AIDS"}
{"id": "article-23408_52", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Autoimmune thyroiditis", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Autoimmune thyroiditis"}
{"id": "article-23408_53", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Inclusion-body myositis", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Inclusion-body myositis"}
{"id": "article-23408_54", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Graft-versus-host disease", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Graft-versus-host disease"}
{"id": "article-23408_55", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Recurrent pregnancy loss", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Recurrent pregnancy loss"}
{"id": "article-23408_56", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Cancer", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Cancer"}
{"id": "article-23408_57", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Severe infections", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Severe infections"}
{"id": "article-23408_58", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Toxic epidermal necrolysis", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Toxic epidermal necrolysis"}
{"id": "article-23408_59", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Stevens-Johnson syndrome", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Stevens-Johnson syndrome"}
{"id": "article-23408_60", "title": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG)", "content": "Neonatal hemochromatosis", "contents": "Immunotherapy -- Mechanism of Action -- Intravenous Immunoglobulins (IVIG). Neonatal hemochromatosis"}
{"id": "article-23408_61", "title": "Immunotherapy -- Mechanism of Action -- Transfer Factor", "content": "Transfer factor is a dialysable extract of leukocytes\u00a0that can transfer cell-mediated immunity from one individual to another. It may be used for several pathologies, including immunodeficiencies, viral infections, malignancies, and recurrent fungal infections. Some patients with type I hypersensitivity disorders have\u00a0demonstrated a response to this product. [10] [11] [12]", "contents": "Immunotherapy -- Mechanism of Action -- Transfer Factor. Transfer factor is a dialysable extract of leukocytes\u00a0that can transfer cell-mediated immunity from one individual to another. It may be used for several pathologies, including immunodeficiencies, viral infections, malignancies, and recurrent fungal infections. Some patients with type I hypersensitivity disorders have\u00a0demonstrated a response to this product. [10] [11] [12]"}
{"id": "article-23408_62", "title": "Immunotherapy -- Mechanism of Action -- Immunosuppressors", "content": "Steroids inhibit cytokine synthesis, affect cell migration, and inhibit the production of leukocytes. Together with chlorambucil, cyclophosphamide acts by covalent alkylation to exert an immunomodulatory effect. This combination inhibits the separation of DNA strands during replication. Methotrexate is an analog of folic acid and blocks pathways essential for DNA synthesis. Azathioprine is a drug that can convert to 6-mercaptopurine to be incorporated into DNA as a fraudulent base. [13]", "contents": "Immunotherapy -- Mechanism of Action -- Immunosuppressors. Steroids inhibit cytokine synthesis, affect cell migration, and inhibit the production of leukocytes. Together with chlorambucil, cyclophosphamide acts by covalent alkylation to exert an immunomodulatory effect. This combination inhibits the separation of DNA strands during replication. Methotrexate is an analog of folic acid and blocks pathways essential for DNA synthesis. Azathioprine is a drug that can convert to 6-mercaptopurine to be incorporated into DNA as a fraudulent base. [13]"}
{"id": "article-23408_63", "title": "Immunotherapy -- Mechanism of Action -- Transplantation", "content": "Transplantation is a promising solution for many rare diseases that can manifest as primary immunodeficiencies, including severe-combined immunodeficiency disorder (SCID), DiGeorge syndrome, Wiskott-Aldrich syndrome, and X-linked agammaglobulinemia. [14]", "contents": "Immunotherapy -- Mechanism of Action -- Transplantation. Transplantation is a promising solution for many rare diseases that can manifest as primary immunodeficiencies, including severe-combined immunodeficiency disorder (SCID), DiGeorge syndrome, Wiskott-Aldrich syndrome, and X-linked agammaglobulinemia. [14]"}
{"id": "article-23408_64", "title": "Immunotherapy -- Mechanism of Action -- Several Immunotherapy Modalities Used in Cancer Treatment", "content": "The use of monoclonal antibodies can be used in cancer immunotherapy (eg, immune checkpoint inhibitors (ICIs). These drugs include pembrolizumab and atezolizumab. These ICIs unlock the immune system, which is then able to recognize tumors and kill them. [4]", "contents": "Immunotherapy -- Mechanism of Action -- Several Immunotherapy Modalities Used in Cancer Treatment. The use of monoclonal antibodies can be used in cancer immunotherapy (eg, immune checkpoint inhibitors (ICIs). These drugs include pembrolizumab and atezolizumab. These ICIs unlock the immune system, which is then able to recognize tumors and kill them. [4]"}
{"id": "article-23408_65", "title": "Immunotherapy -- Mechanism of Action -- Several Immunotherapy Modalities Used in Cancer Treatment", "content": "Cytokines\u00a0have successfully\u00a0treated certain malignancies. For example, IL-2 combined with interferon-\u03b3 for renal carcinoma, interferon-\u03b1 and \u03b2 for hairy leukemia, and TNF-\u03b1 used in various tumors caused a notable reduction of the mass. These cytokines upregulated the immune system by stimulating T-cell and NK cell activation and increased MHC class I expression. CAR T-cell therapy, or Chimeric Antigen Receptor T-cell therapy, is a groundbreaking immunotherapy approach used to treat certain types of cancer. Here are the key principles: [15] [6]", "contents": "Immunotherapy -- Mechanism of Action -- Several Immunotherapy Modalities Used in Cancer Treatment. Cytokines\u00a0have successfully\u00a0treated certain malignancies. For example, IL-2 combined with interferon-\u03b3 for renal carcinoma, interferon-\u03b1 and \u03b2 for hairy leukemia, and TNF-\u03b1 used in various tumors caused a notable reduction of the mass. These cytokines upregulated the immune system by stimulating T-cell and NK cell activation and increased MHC class I expression. CAR T-cell therapy, or Chimeric Antigen Receptor T-cell therapy, is a groundbreaking immunotherapy approach used to treat certain types of cancer. Here are the key principles: [15] [6]"}
{"id": "article-23408_66", "title": "Immunotherapy -- Mechanism of Action -- Several Immunotherapy Modalities Used in Cancer Treatment", "content": "CAR Structure: CARs are synthetic receptors that redirect T-cells to recognize and attack cancer cells. They consist of an extracellular antigen-binding domain, a transmembrane domain, and intracellular signaling domains.", "contents": "Immunotherapy -- Mechanism of Action -- Several Immunotherapy Modalities Used in Cancer Treatment. CAR Structure: CARs are synthetic receptors that redirect T-cells to recognize and attack cancer cells. They consist of an extracellular antigen-binding domain, a transmembrane domain, and intracellular signaling domains."}
{"id": "article-23408_67", "title": "Immunotherapy -- Mechanism of Action -- Several Immunotherapy Modalities Used in Cancer Treatment", "content": "Antigen Recognition: The extracellular domain of the CAR is engineered to recognize a specific antigen present on the surface of cancer cells. This antigen is often a tumor-associated antigen (TAA) or a cancer-specific antigen.", "contents": "Immunotherapy -- Mechanism of Action -- Several Immunotherapy Modalities Used in Cancer Treatment. Antigen Recognition: The extracellular domain of the CAR is engineered to recognize a specific antigen present on the surface of cancer cells. This antigen is often a tumor-associated antigen (TAA) or a cancer-specific antigen."}
{"id": "article-23408_68", "title": "Immunotherapy -- Mechanism of Action -- Several Immunotherapy Modalities Used in Cancer Treatment", "content": "T-Cell Activation: Upon binding to the target antigen, the CAR activates the T-cell, leading to its proliferation, cytokine release, and cytotoxic activity against the cancer cell.", "contents": "Immunotherapy -- Mechanism of Action -- Several Immunotherapy Modalities Used in Cancer Treatment. T-Cell Activation: Upon binding to the target antigen, the CAR activates the T-cell, leading to its proliferation, cytokine release, and cytotoxic activity against the cancer cell."}
{"id": "article-23408_69", "title": "Immunotherapy -- Mechanism of Action -- Several Immunotherapy Modalities Used in Cancer Treatment", "content": "Persistence and Memory: CAR T-cells are designed to persist in the body and form memory cells, providing long-term surveillance against cancer recurrence.", "contents": "Immunotherapy -- Mechanism of Action -- Several Immunotherapy Modalities Used in Cancer Treatment. Persistence and Memory: CAR T-cells are designed to persist in the body and form memory cells, providing long-term surveillance against cancer recurrence."}
{"id": "article-23408_70", "title": "Immunotherapy -- Mechanism of Action -- Several Immunotherapy Modalities Used in Cancer Treatment", "content": "Treatment Process: The CAR T-cell therapy process involves collecting a patient's T-cells through leukapheresis, genetically engineering them to express the CAR, expanding them in the laboratory, and then reinfusing them into the patient.", "contents": "Immunotherapy -- Mechanism of Action -- Several Immunotherapy Modalities Used in Cancer Treatment. Treatment Process: The CAR T-cell therapy process involves collecting a patient's T-cells through leukapheresis, genetically engineering them to express the CAR, expanding them in the laboratory, and then reinfusing them into the patient."}
{"id": "article-23408_71", "title": "Immunotherapy -- Mechanism of Action -- Several Immunotherapy Modalities Used in Cancer Treatment", "content": "Clinical Applications: CAR T-cell therapy has shown remarkable success in treating certain hematological malignancies, such as B-cell acute lymphoblastic leukemia (B-ALL) and certain types of non-Hodgkin lymphoma (NHL). It is also being investigated for solid tumors.", "contents": "Immunotherapy -- Mechanism of Action -- Several Immunotherapy Modalities Used in Cancer Treatment. Clinical Applications: CAR T-cell therapy has shown remarkable success in treating certain hematological malignancies, such as B-cell acute lymphoblastic leukemia (B-ALL) and certain types of non-Hodgkin lymphoma (NHL). It is also being investigated for solid tumors."}
{"id": "article-23408_72", "title": "Immunotherapy -- Mechanism of Action -- Several Immunotherapy Modalities Used in Cancer Treatment", "content": "Challenges and Side Effects: Despite its efficacy, CAR T-cell therapy can be associated with side effects such as cytokine release syndrome (CRS) and neurotoxicity. Managing these side effects and improving the therapy's safety profile are ongoing research areas.", "contents": "Immunotherapy -- Mechanism of Action -- Several Immunotherapy Modalities Used in Cancer Treatment. Challenges and Side Effects: Despite its efficacy, CAR T-cell therapy can be associated with side effects such as cytokine release syndrome (CRS) and neurotoxicity. Managing these side effects and improving the therapy's safety profile are ongoing research areas."}
{"id": "article-23408_73", "title": "Immunotherapy -- Administration", "content": "IVIG can be administered intravenously\u00a0with a dosage of 0.4 g/kg for\u00a05 days to treat Guillain\u2013Barr\u00e9 syndrome, but the dose varies depending on the pathology. Low-dose cyclophosphamide has had a more significant impact on cell-mediated immunity. In humans, a low-dose bolus of 600 mg/m B-cells decreases more than T-cells, and among T-cells, the CD8 subset diminishes more than CD4 cells.", "contents": "Immunotherapy -- Administration. IVIG can be administered intravenously\u00a0with a dosage of 0.4 g/kg for\u00a05 days to treat Guillain\u2013Barr\u00e9 syndrome, but the dose varies depending on the pathology. Low-dose cyclophosphamide has had a more significant impact on cell-mediated immunity. In humans, a low-dose bolus of 600 mg/m B-cells decreases more than T-cells, and among T-cells, the CD8 subset diminishes more than CD4 cells."}
{"id": "article-23408_74", "title": "Immunotherapy -- Adverse Effects", "content": "Adverse effects of immunotherapy include:", "contents": "Immunotherapy -- Adverse Effects. Adverse effects of immunotherapy include:"}
{"id": "article-23408_75", "title": "Immunotherapy -- Adverse Effects", "content": "Cyclophosphamide and chlorambucil include bone marrow toxicity; therefore, leukopenia requires monitoring. Azathioprine produces reductions of both T and B-lymphocytes. Giving transfer factor requires caution in patients with Type I hypersensitivity reactions to prevent anaphylaxis. Interleukins must be given in a low dose to prevent side effects and decrease morbidity. Glucocorticoid therapy causes negative calcium balance, leading to osteoporosis, increased appetite,\u00a0central\u00a0obesity, impaired wound healing, increased risk of infection, suppression of the hypothalamic-pituitary-adrenal axis, and growth arrest in children. Other side effects\u00a0include myopathy, avascular necrosis, hypertension, plethora, hyperlipidemia, and edema. Adverse\u00a0effects of NSAID therapy include gastritis, duodenal and gastric ulcers, decreased creatinine clearance, acute renal failure, interstitial nephritis, confusion, memory loss, and personality changes, especially in older patients.", "contents": "Immunotherapy -- Adverse Effects. Cyclophosphamide and chlorambucil include bone marrow toxicity; therefore, leukopenia requires monitoring. Azathioprine produces reductions of both T and B-lymphocytes. Giving transfer factor requires caution in patients with Type I hypersensitivity reactions to prevent anaphylaxis. Interleukins must be given in a low dose to prevent side effects and decrease morbidity. Glucocorticoid therapy causes negative calcium balance, leading to osteoporosis, increased appetite,\u00a0central\u00a0obesity, impaired wound healing, increased risk of infection, suppression of the hypothalamic-pituitary-adrenal axis, and growth arrest in children. Other side effects\u00a0include myopathy, avascular necrosis, hypertension, plethora, hyperlipidemia, and edema. Adverse\u00a0effects of NSAID therapy include gastritis, duodenal and gastric ulcers, decreased creatinine clearance, acute renal failure, interstitial nephritis, confusion, memory loss, and personality changes, especially in older patients."}
{"id": "article-23408_76", "title": "Immunotherapy -- Contraindications", "content": "Patients with T-cell deficiencies (including SCID) should not be vaccinated with the live-attenuated vaccine because there is a danger that the antigen will reverse its pathogenicity and cause illness. Patients with IgA deficiency should not receive IgG preparations that are not highly purified because there is a danger of a hypersensitivity reaction. If the immune system does not recognize the IgA in the preparation, this can be life-threatening. Patients with DiGeorge syndrome should not be transplanted with a thymus older than 14 weeks because a graft-versus-host reaction may occur.\u00a0The donor can be\u00a0a sibling or a parent if genetic compatibility exists. Blood group compatibility for major antigens (such as the ABO system and Rh system) must match. [14] [16]", "contents": "Immunotherapy -- Contraindications. Patients with T-cell deficiencies (including SCID) should not be vaccinated with the live-attenuated vaccine because there is a danger that the antigen will reverse its pathogenicity and cause illness. Patients with IgA deficiency should not receive IgG preparations that are not highly purified because there is a danger of a hypersensitivity reaction. If the immune system does not recognize the IgA in the preparation, this can be life-threatening. Patients with DiGeorge syndrome should not be transplanted with a thymus older than 14 weeks because a graft-versus-host reaction may occur.\u00a0The donor can be\u00a0a sibling or a parent if genetic compatibility exists. Blood group compatibility for major antigens (such as the ABO system and Rh system) must match. [14] [16]"}
{"id": "article-23408_77", "title": "Immunotherapy -- Enhancing Healthcare Team Outcomes", "content": "The use of IVIG has expanded significantly over the past\u00a03 decades.\u00a0Providing care to patients with immune deficiencies is most effective with an interprofessional team that includes clinicians (MDs, DOs, NPs, PAs), specialists, hematology nurses, and pharmacists. While IVIG is effective, patients need to understand that the therapy is not benign and is associated with adverse effects. Close monitoring of patients is necessary because of allergies, anaphylaxis, and graft-versus-host reactions. Given the potential for adverse events with immunotherapy, the entire team must be vigilant for these reactions. The pharmacist must have close involvement with nursing and the clinician staff, with all members of the interprofessional team informed and communicating regarding the adverse event profile. This is so immunotherapy has the best chance to help the patient with minimal chance for\u00a0adverse effects.", "contents": "Immunotherapy -- Enhancing Healthcare Team Outcomes. The use of IVIG has expanded significantly over the past\u00a03 decades.\u00a0Providing care to patients with immune deficiencies is most effective with an interprofessional team that includes clinicians (MDs, DOs, NPs, PAs), specialists, hematology nurses, and pharmacists. While IVIG is effective, patients need to understand that the therapy is not benign and is associated with adverse effects. Close monitoring of patients is necessary because of allergies, anaphylaxis, and graft-versus-host reactions. Given the potential for adverse events with immunotherapy, the entire team must be vigilant for these reactions. The pharmacist must have close involvement with nursing and the clinician staff, with all members of the interprofessional team informed and communicating regarding the adverse event profile. This is so immunotherapy has the best chance to help the patient with minimal chance for\u00a0adverse effects."}
{"id": "article-23408_78", "title": "Immunotherapy -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Immunotherapy -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}